PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients-Reference-Cited by-同舟云学术

PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients

Published:2021-07 Issue: Volume: Page:
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Remon Jordi^ORCID,Girard Nicolas,Novello Silvia,de Castro Javier,Bigay-Game Laurence,Bernabé Reyes,Greillier Laurent,Mosquera Joaquin^ORCID,Cousin Sophie,Juan Oscar,Sampayo Miguel^ORCID,Besse Benjamin

Funder

Merck Sharp and Dohme

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. The 2015 World Health Organization classification of tumors of the thymus: continuity and changes;Marx;J Thorac Oncol,2015

2. The impact of thymoma histotype on prognosis in a worldwide database;Weis;J Thorac Oncol,2015

3. Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET);Montanez;Ann Oncol,2020

4. A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma;Gbolahan;J Thorac Oncol,2018

5. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy;Zucali;J Clin Oncol,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing cancer immunotherapy and antiangiogenic therapy by regulating gut microbes: Opportunities and challenges;MedComm – Oncology;2024-08-08

2. Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas;Clinical Lung Cancer;2024-06

3. A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors;JTO Clinical and Research Reports;2024-02

4. Progress in the treatment of malignant ascites;Critical Reviews in Oncology/Hematology;2024-02

5. The Molecular Landscape of Thymic Epithelial Tumors: A Comprehensive Review;International Journal of Molecular Sciences;2024-01-26